This article was originally published on 27 May 2015 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.
The burden of hMPV in children
Human metapneumovirus (hMPV), first described in 2001, is estimated to be the second most common cause of lower respiratory tract infection (LRTI) in young children globally, behind only RSV. The virus causes a spectrum of illness ranging from mild upper respiratory tract disease to severe bronchiolitis and pneumonia requiring hospitalisation. Like RSV, hMPV disproportionately affects infants under two years of age, elderly individuals and the immunocompromised.
Population seroprevalence studies indicate that virtually all children have been infected by hMPV by the age of five, suggesting that primary infection in infancy is near-universal in most regions. Despite this substantial disease burden, hMPV has received remarkably little attention from the vaccine development community compared to RSV, influenza and other respiratory pathogens.
Only one active clinical-stage hMPV vaccine programme was identified globally at the time of publication (NIAID)
Why only one clinical programme?
Several factors explain the neglect. First, hMPV was only identified in 2001 - some 50 years after RSV - meaning the scientific and commercial groundwork is commensurately less advanced. Second, hMPV and RSV cause sufficiently similar clinical presentations that some stakeholders have questioned whether combination coverage might be achievable within a single vaccine platform. If an RSV vaccine can be developed to also cover hMPV, the commercial rationale for an hMPV-specific programme diminishes.
Third, and critically, the commercial dynamics of the paediatric respiratory vaccine market are already highly competitive. Manufacturers developing RSV vaccines - including Novavax, AstraZeneca/MedImmune and GSK - have invested heavily in understanding RSV immunology. Pivoting to a less characterised target with an uncertain regulatory pathway carries greater risk.
"The commercial logic for an hMPV-specific programme is eroded if an RSV vaccine platform could ultimately be engineered to provide dual coverage."
The NIAID programme and VacZine Analytics outlook
The sole clinical-stage programme at time of writing was being developed by the US National Institute of Allergy and Infectious Diseases (NIAID), consistent with the institute's role in funding early-stage work on diseases that lack commercial champions. VacZine Analytics tracks this area under its MarketVIEW product reference VAMV62.
Until a large commercial sponsor commits meaningfully to hMPV - whether through an hMPV-specific programme or through combined RSV/hMPV platform development - the vaccine will remain the poor cousin of RSV: well recognised in the scientific literature but commercially under-served.